VALN stock news · Valneva
Get alerts for VALN
Follow Valneva (VALN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VALNValneva shares details from its earnings call for the second quarter of 2026.
NeutralValneva reported lower first-half product sales, but kept its 2026 sales forecast and reported cash above €120 million. The mixed update leaves its outlook unchanged.
The UK has taken back its permission for Valneva's chikungunya vaccine.
NeutralValneva lost U.K. approval for its chikungunya vaccine, but had already stopped selling it there. Approvals elsewhere remain unchanged, so the story points to little change for the company.
The UK has taken back its permission for Valneva's chikungunya vaccine.
NeutralValneva lost UK approval for its chikungunya vaccine, but it had already stopped selling it there. Other country approvals remain, so the news leaves its current business outlook largely unchanged.
12 health care companies saw big changes in their stock prices after the market closed on Wednesday.
NeutralValneva shares rose 20.6% to $7.09 in Wednesday's after-hours session. The article gives no company news, so this does not change how we read its business.
Pfizer and Valneva's application for a Lyme disease vaccine receives validation from European regulators.
Good for VALNValneva's stock surged following the EMA's validation of their Lyme disease vaccine application, indicating strong market interest.